Maja Miloslavsky

Maja Miloslavsky

UNVERIFIED PROFILE

Are you Maja Miloslavsky?   Register this Author

Register author
Maja Miloslavsky

Maja Miloslavsky

Publications by authors named "Maja Miloslavsky"

Are you Maja Miloslavsky?   Register this Author

6Publications

213Reads

20Profile Views

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

N Engl J Med 2014 Jan;370(4):322-33

From Butler Hospital, Providence, RI (S.S.); Brigham and Women's Hospital, Boston (R.S.); University College London, Institute of Neurology, London (N.C.F.); University of Göteborg, Sahlgrenska University Hospital, Mölndal, Sweden (K.B.); University of Pittsburgh, Pittsburgh (W.K.); Veterans Affairs Medical Center, Seattle (M.R.); Cleo Roberts Center for Clinical Research/Sun Health Research Institute, Sun City, AZ (M.S.); Columbia University (L.S.H.) and New York University Langone Medical Center (S.F.), New York; University of Rochester School of Medicine and Dentistry, Rochester, NY (A.P.P.); Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA (M.R., N.K., B.N., V.G., M.M., D.W., Y.L., I.C.T., E.L., E.Y., H.R.B.); Janssen Research and Development, Titusville, NJ (J.L.); Global R&D Partners and the University of California, San Diego - both in San Diego (M.G.); and Pfizer, Collegeville, PA (R.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1304839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159618PMC
January 2014